Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Sacubitril Sodium
2. 149690-05-1
3. Ahu-377 Sodium
4. Sacubitril (sodium)
5. Mop72gep8z
6. Sodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
7. Unii-mop72gep8z
8. Sacubitril Sodium Salt
9. Sacubitril Sodium [mi]
10. Schembl21239956
11. Dtxsid90164362
12. Hy-15407b
13. (1,1'-biphenyl)-4-pentanoic Acid, Gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl-, 4-ethyl Ester, Sodium Salt (1:1), (alphar,gammas)-
14. Cs-0079358
15. A937423
16. Q27284149
17. (1,1'-biphenyl)-4-pentanoic Acid, .gamma.-((3-carboxy-1-oxopropyl)amino)-.alpha.-methyl-, 4-ethyl Ester, Sodium Salt (1:1), (.alpha.r,.gamma.s)-
18. Sodium 4-(((2s,4r)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate
| Molecular Weight | 433.5 g/mol |
|---|---|
| Molecular Formula | C24H28NNaO5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 12 |
| Exact Mass | 433.18651728 g/mol |
| Monoisotopic Mass | 433.18651728 g/mol |
| Topological Polar Surface Area | 95.5 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 556 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6260
Start Marketing Date : 2016-05-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46708-941
Start Marketing Date : 2025-08-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65727-079
Start Marketing Date : 2019-04-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 69766-057
Start Marketing Date : 2018-10-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 72023-0012
Start Marketing Date : 2024-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 72023-0011
Start Marketing Date : 2024-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 72375-0012
Start Marketing Date : 2024-11-05
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2024
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubitril is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.
Lead Product(s): Sacubitril Sodium,Valsartan,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
Details : Sacubitril is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of essential hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DWJ1445 (sacubitril) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Sacubitril Sodium,Valsartan,DWC202506
Therapeutic Area: Undisclosed Brand Name: DWJ1445
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan,DWC202506
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers
Details : DWJ1445 (sacubitril) is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : DWJ1445
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin II receptor blocker (ARB), the combination is indicated for the treatment of chronic heart failure and reduced ejection fraction.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Sacubitril-Valsartan-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MSN Launches Sacubitril/Valsartan Tablets In U.S. After Legal Win
Details : Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin II receptor blocker (ARB), the combination is indicated for the treatment of chronic heart failure and reduced ejection fraction.
Product Name : Sacubitril-Valsartan-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® ...
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Entresto-Generic (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives U.S. FDA Approval for Sacubitril and Valsartan Tablets
Details : Entresto-Generic (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Essential Hypertension.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Essential Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
OnArni (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: OnArni
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
USV Introduces OnArni, FDC of Sacubitril, Valsartan, For HF Management
Details : OnArni (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : OnArni
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Sacubright
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exemed Receives CDSCO Nod For Study of Sacubitril Plus Valsartan Sustained-Release Tablet
Details : Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : Sacubright
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Unit Gets USFDA Nod For Generic Drug
Details : Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Packaging :
Approval Date : 2025-01-13
Application Number : 213627
Regulatory Info : RX
Registration Country : USA
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 49MG;51MG
Packaging :
Approval Date : 2025-01-13
Application Number : 213627
Regulatory Info : RX
Registration Country : USA
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 97MG;103MG
Packaging :
Approval Date : 2025-01-13
Application Number : 213627
Regulatory Info : RX
Registration Country : USA
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 49MG;51MG
Packaging :
Approval Date : 12-12-2025
Application Number : 90866
Regulatory Info : Authorized
Registration Country : Spain
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 24MG;26MG
Packaging :
Approval Date : 11-12-2025
Application Number : 90865
Regulatory Info : Authorized
Registration Country : Spain
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 97MG;103MG
Packaging :
Approval Date : 12-12-2025
Application Number : 90867
Regulatory Info : Authorized
Registration Country : Spain
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : ENTRESTO
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Packaging :
Approval Date : 2015-07-07
Application Number : 207620
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : ENTRESTO
Dosage Form : TABLET;ORAL
Dosage Strength : 49MG;51MG
Packaging :
Approval Date : 2015-07-07
Application Number : 207620
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : ENTRESTO
Dosage Form : TABLET;ORAL
Dosage Strength : 97MG;103MG
Packaging :
Approval Date : 2015-07-07
Application Number : 207620
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Packaging :
Approval Date : 2024-08-22
Application Number : 213604
Regulatory Info : RX
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Approval Date : 2025-01-13
Application Number : 213627
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 49MG;51MG
Approval Date : 2025-01-13
Application Number : 213627
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 97MG;103MG
Approval Date : 2025-01-13
Application Number : 213627
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 49MG;51MG
Approval Date : 2024-05-28
Application Number : 213682
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 97MG;103MG
Approval Date : 2024-05-28
Application Number : 213682
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Approval Date : 2024-09-16
Application Number : 213764
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 49MG;51MG
Approval Date : 2024-09-16
Application Number : 213764
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Approval Date : 2024-08-30
Application Number : 213680
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 97MG;103MG
Approval Date : 2024-05-28
Application Number : 213676
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Brand Name : SACUBITRIL AND VALSARTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 24MG;26MG
Approval Date : 2024-05-28
Application Number : 213605
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 49MG;51MG
Packaging :
Approval Date : 12-12-2025
Application Number : 90866
Regulatory Info : Authorized
Registration Country : Spain
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 24MG;26MG
Packaging :
Approval Date : 11-12-2025
Application Number : 90865
Regulatory Info : Authorized
Registration Country : Spain
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Valsartan Disodium; Sacubitril Sodium
Brand Name : Sacubitril/Valsartan Pensa
Dosage Form : Film Coated Tablet
Dosage Strength : 97MG;103MG
Packaging :
Approval Date : 12-12-2025
Application Number : 90867
Regulatory Info : Authorized
Registration Country : Spain
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Sacuval™ 24 mg/26 mg
Dosage Form : Film Coated Tablet
Dosage Strength : 24mg; 26mg
Packaging :
Approval Date : 28-10-2024
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Sacuval™ 97 mg/103 mg
Dosage Form : Film Coated Tablet
Dosage Strength :
Packaging :
Approval Date : 28-10-2024
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Entresto
Dosage Form : Film-Coated Tablet
Dosage Strength : 103mg; 97mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Neparvis
Dosage Form : Film-Coated Tablet
Dosage Strength : 26mg; 24mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Entresto
Dosage Form : Film Coated Tablet
Dosage Strength : 97MG; 103 MG
Packaging :
Approval Date : 02-11-2021
Application Number : 151058006IP1
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Neparvis
Dosage Form : Film Coated Tablet
Dosage Strength : 97MG; 103 MG
Packaging :
Approval Date : 24-06-2016
Application Number : 1161103006
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Entresto
Dosage Form : Film Coated Tablet
Dosage Strength : 97MG;103MG
Packaging :
Approval Date : 16-06-2025
Application Number : 151058006IP3
Regulatory Info : Authorized
Registration Country : Spain

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Market Place
Reply
07 Jun 2022
Reply
16 Mar 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Sacubitril Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sacubitril Sodium manufacturer or Sacubitril Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sacubitril Sodium manufacturer or Sacubitril Sodium supplier.
A Sacubitril manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sacubitril, including repackagers and relabelers. The FDA regulates Sacubitril manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sacubitril API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sacubitril manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Sacubitril supplier is an individual or a company that provides Sacubitril active pharmaceutical ingredient (API) or Sacubitril finished formulations upon request. The Sacubitril suppliers may include Sacubitril API manufacturers, exporters, distributors and traders.
click here to find a list of Sacubitril suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Sacubitril DMF (Drug Master File) is a document detailing the whole manufacturing process of Sacubitril active pharmaceutical ingredient (API) in detail. Different forms of Sacubitril DMFs exist exist since differing nations have different regulations, such as Sacubitril USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sacubitril DMF submitted to regulatory agencies in the US is known as a USDMF. Sacubitril USDMF includes data on Sacubitril's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sacubitril USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sacubitril suppliers with USDMF on PharmaCompass.
A Sacubitril written confirmation (Sacubitril WC) is an official document issued by a regulatory agency to a Sacubitril manufacturer, verifying that the manufacturing facility of a Sacubitril active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sacubitril APIs or Sacubitril finished pharmaceutical products to another nation, regulatory agencies frequently require a Sacubitril WC (written confirmation) as part of the regulatory process.
click here to find a list of Sacubitril suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sacubitril as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sacubitril API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sacubitril as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sacubitril and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sacubitril NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sacubitril suppliers with NDC on PharmaCompass.
Sacubitril Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sacubitril GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sacubitril GMP manufacturer or Sacubitril GMP API supplier for your needs.
A Sacubitril CoA (Certificate of Analysis) is a formal document that attests to Sacubitril's compliance with Sacubitril specifications and serves as a tool for batch-level quality control.
Sacubitril CoA mostly includes findings from lab analyses of a specific batch. For each Sacubitril CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sacubitril may be tested according to a variety of international standards, such as European Pharmacopoeia (Sacubitril EP), Sacubitril JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sacubitril USP).